Soriano A, Morata L
Alex Soriano, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona Helios Building, first floor, desk 25. Villarroel 170, Barcelona 08036. Spain.
Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):24-28.
Ceftobiprole is a new cephalosporin with an extended spectrum activity against the majority of microorganisms isolated in bacteremia including methicillin-susceptible (MSSA) and -resistant S. aureus (MRSA). This antibiotic has demonstrated a potent activity against MRSA in animal models of endocarditis in monotherapy but particularly in combination with daptomycin, suggesting that this combination could be a future option to improve the outcome of staphylococcal endovascular infections. In addition, the extended-spectrum ceftobiprole activity, including coagulase-negative staphylococci, Enterococcus faecalis, Enterobacteriaceae and Pseudomonas aeruginosa represents an advantage for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as in catheter-related bacteremia.
头孢比普是一种新型头孢菌素，对从菌血症中分离出的大多数微生物具有广谱活性，包括甲氧西林敏感金黄色葡萄球菌（MSSA）和耐甲氧西林金黄色葡萄球菌（MRSA）。在单药治疗的感染性心内膜炎动物模型中，这种抗生素已证明对MRSA具有强效活性，尤其是与达托霉素联合使用时，这表明这种联合用药可能是改善葡萄球菌血管内感染治疗结果的一种未来选择。此外，头孢比普的广谱活性，包括凝固酶阴性葡萄球菌、粪肠球菌、肠杆菌科和铜绿假单胞菌，使其在可能由多种微生物引起的菌血症（如导管相关菌血症）的经验性治疗中具有优势。
